Change in number of shares and votes in Boule Diagnostics

Stockholm, Sweden, December 30, 2022 – Boule Diagnostics AB (publ) (“Boule” or the “Company”) (Nasdaq Stockholm: BOUL) has, as previously announced, carried out a preferential rights issue of shares, which has resulted in changes in the number of shares and votes in Boule.

Prior to the preferential rights issue of shares, which was resolved by the board of directors on October 3, 2022, and approved by an extraordinary general meeting on November 1, 2022, there were in total 19,416,552 shares and votes in the Company. The number of shares and votes in the Company has increased with 19,416,552 through the preferential rights issue.

As of December 30, 2022, there are a total of 38,833,104 shares and votes in Boule.

For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Annette Colin, CFO, Boule Diagnostics AB, phone +46 (0)70-319 06 76

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on December 30, 2022, at 15.00 CET.

About Boule Diagnostics AB
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

Boule Diagnostics AB – Change in number of shares (EN) 221230